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Hospitalized patients initially on intravenous antibiotics can be safely switched to an oral equivalent within the third
day of admission once clinical stability is established. This conversion has many advantages as fewer complications,
less healthcare costs and earlier hospital discharge. The three types of intravenous to oral conversion include
sequential, switch, and step-down therapy. The aim of the study was to evaluate the practice of switching from
intravenous to oral antibiotics, its types and its impact on the clinical outcomes. This was a retrospective observational
study conducted in three Lebanese hospitals over a period of six months. Adult inpatients on intravenous antibiotics
for 2 days and more were eligible for study enrollment. Excluded were patients admitted to care or surgery units, or
those with gastrointestinal diseases, infections that require prolonged course of parenteral therapy, or malignancies.
The study showed that among 452 intravenous antibiotic courses from 356 patients who were eligible for conversion,
only one third were switched and the others continued on intravenous antibiotics beyond day 3 (P <0.0001). The mean
duration of intravenous therapy of converted patients was markedly shorter than the non-converted (P <0.0001) with
no significant change in the mean length of stay. Fluoroquinolones and macrolides were the most commonly
converted antibiotics. However, the sequential therapy was the major type of conversion practiced in this study.
Based on the study findings, a significant proportion of patients can be considered for switch. This emphasizes
an important gap in the field of conversion from intravenous to oral antibiotic therapy and the need for
integration and reinforcement of the appropriate Antibiotic Stewardship Programs in hospitals.
Keywords: Intravenous to oral antibiotics; Switch therapy; IV to PO conversion; Clinical outcomes; Antibiotic
stewardshipIntroduction
The appropriate use of antibiotics depends on the selec-
tion of an agent capable of achieving a desired serum
concentration to target the presumed organism at the
site of infection with an acceptable safety profile (Burke
2003; Davey et al. 2006). Inappropriate and unnecessary
antimicrobial usage leads to an increase in healthcare
costs and pathogen resistance (Spellberg et al. 2008).
Antimicrobial Stewardship Programs (ASPs) have
been developed to limit unnecessary antimicrobial use
through reassessment of diagnosis and therapy within
48 to 72 hours, streamlining/de-escalation of anti-
biotics based on culture/sensitivity data, and the use
of antibiotics for the shortest duration needed (Petrak* Correspondence: zeina_sh@hotmail.com
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in any medium, provided the original work is pet al. 2003; Dellit et al. 2007). Clinical pharmacists,
with the help of infectious disease (ID) team, have an
integral role in a day-to-day practice for the judicious
use of antibiotics within a short period of time thus
promoting further patient safety (Septimus and Owens
2011; ASHP 2010).
Most of inpatients are prescribed intravenous (IV)
antibiotics for an extended duration of therapy while an
oral (PO) route is possible. Approximately one third of
all inpatients initiated on IV antibiotics are eligible for
switch to an oral equivalent (McLaughlin et al. 2005).
Short intravenous course of therapy for 2–3 days followed
by oral medications to complete the course of therapy is
beneficial to many patients except in conditions of
serious/life-threatening infections, in critically ill patients,
or in the presence of contraindications to oral administra-
tion as in case of nothing per os (NPO) or comatose pa-
tients (Septimus and Owens 2011; ASHP 2010; Bond ands an Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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oral medication produces serum levels comparable to
those achieved through IV form with equivalent clinical
outcomes as reduction in the length of hospital stay (LOS)
and the duration of IV therapy, along with fewer compli-
cations, less patient inconvenience, less healthcare costs
and earlier hospital discharge (Septimus and Owens 2011;
Lee et al. 2012; Sevinç et al. 1999).
IV to PO conversion guidelines, a component of ASPs,
are implemented in hospitals of developed countries and
constitute a strategy in daily practice, whereas few hospi-
tals in Lebanon adopt these programs (Septimus and
Owens 2011; Kuper 2008). Patients fulfilling the prede-
fined criteria for switch are evaluated. These criteria are
based on both drug and host factors (ASHP 2010). Drug
factors include high degree of activity against presumed/
known pathogens, high oral bioavailability, low resist-
ance potential, and tolerance with a good safety profile
(McLaughlin et al. 2005). Host factors require sufficient
absorption of an oral antibiotic with no impairment
of gastrointestinal tract and stable clinical condition
(Septimus and Owens 2011; Kuper 2008). Improvement
of clinical status is evaluated according to temperature,
white blood cell count, absence of signs of sepsis, as well
as specific criteria for particular infections (Septimus
and Owens 2011; Bond and Raehl 2005; Kuper 2008;
Gross et al. 2001; Kuti et al. 2002).
There exist three types of IV to PO conversion therapy:
sequential, switch and step-down therapies (Kuper 2008).
A sequential therapy consists of converting from IV to PO
agents with the same compound; a switch therapy is
converting with an identical potency; and a step-down
therapy is converting with a reduced potency (Kuper
2008). The choice of the type depends on the anti-
microbials class and the availability of an oral equiva-
lent (Septimus and Owens 2011).
Most of the studies conducted for the evaluation of
IV to PO antimicrobial conversion were interventional
studies (Bailey et al. 1997; Kuti et al. 2002; Davis et al.
2005; Ho et al. 2005; Yen et al. 2012; Halley 2000), but
have been restricted to certain antibiotic classes (Fischer
et al. 2003; Kuti et al. 2002; Davis et al. 2005; Ho et al.
2005; Yen et al. 2012; Pablos et al. 2005; Buyle et al.
2010; Marra et al. 2000) and certain medical conditions
(Davis et al. 2005; Cunha 2001; Ramirez and Bordon
2001; Fine et al. 2003). All of which were mostly
allocated in the USA (Davis et al. 2005; Galanter et al.
2010; Lau et al. 2011; Glemaud 2000; Fox et al. 2003),
others were done in Canada (Ho et al. 2005; Marra et al.
2000; Frighetto et al. 1995; Malfair et al. 1996; Zamin
et al. 1997), Ireland (Dunn et al. 2011, Al-Eidan et al.
1999, Chan et al. 1995), Spain (Castro-Guardiola et al.
2001; Martínez et al. 2000), Netherlands (Oosterheert
et al. 2006) and Switzerland (Mertz et al. 2009; Sennet al. 2004). These studies demonstrated comparable
clinical efficacy rates without serious adverse events and
improvements in therapeutic and financial outcomes
(Fischer et al. 2003; Ho et al. 2005; Galanter et al. 2010).
The aim of the study was to evaluate the practice of
switching from IV to PO antibiotics based on predefined
eligibility criteria and its impact on clinical outcomes as
the duration of IV antibiotic therapy and LOS, and to
assess the correlation between the type of conversion
and antibiotic classes.
Methods
Study design and study population
This was a retrospective observational study conducted
in three Lebanese university teaching hospitals. Patient’s
information was obtained from the medical records
of each site. All patients hospitalized for more than
24 hours were screened for possible inclusion. The
Institutional Review Board of the three hospitals and
the School of Pharmacy at the Lebanese International
University approved the study.
Inclusion and exclusion criteria
Adult inpatients receiving an IV antibiotic for more than
48 hours were included. Excluded from the analysis were
patients: younger than 18 years of age, not eligible for
oral formulation based upon a permanent physiologic
condition (e.g. malabsorption syndrome, partial or total
removal of stomach, or short bowel syndrome), patients
with malignancies or admitted to cardiac/intensive care
and surgery units. In addition to those who received IV
prophylactic antibiotics, or if a prolonged course of IV an-
tibiotics was required as in case of osteomyelitis, meningi-
tis, Staphylococcus aureus bacteremia and endocarditis.
Data collection
A structured questionnaire was developed and data were
recorded by the principle investigator without any inter-
ference on results. This questionnaire has been previ-
ously validated by the School of Pharmacy. It is divided
into three parts. The first part included demographic
characteristics of patients, co-morbidities, allergies, pri-
mary diagnosis or presumed indication for antibiotic
therapy, microbiological results if available. The second
included the antibiotics administered, specifying the
type, route of administration, duration of IV therapy,
and LOS. Additional data were recorded if a switch from
the initial prescribed antibiotic was done, this included
the time of switch along with the type of modification
whether discontinuation or conversion from IV to PO
therapy. In the third part, daily recording of signs and
symptoms to assess clinical stability throughout the hos-
pital stay (hemodynamic stability as temperature, blood
pressure, heart rate, white blood cell count, respiratory
2073 patients 
screened 
1469 patients on IV 
antibiotics
Patients excluded
293 with no antibiotics 
311 on PO antibiotics
Patients excluded
107 IV antibiotics <48 hrs
979 medical conditions*
383 patients included
Figure 1 Flowchart for identification of patients eligible to the
study. The identification of patients eligible for the inclusion criteria
in the study was done in 2 steps. *Medical conditions for excluded
patients include pediatrics, surgery and care units, malignancies,
severe/life-threatening infections, acute respiratory distress
syndrome, central nervous system/seizures/meningitis, and
gastrointestinal problems. Abbreviations: IV, intravenous; PO, oral.
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assessment of cough, dyspnea and oxygen saturation for
respiratory tract infections, and redness, heat and indur-
ation for skin and soft tissue infections).
Outcomes
The primary outcome of this study was to evaluate
the practice of the utilization of IV antibiotic therapy
through an assessment of the switch according to prede-
fined criteria for clinical stability. Criteria for IV to PO
switch was defined as patients who had received an IV
antibiotic for ≥ 48 hours and were able to tolerate oral
therapy; no vomiting or diarrhea or NPO; and clinical
improvement with temperature less than 38°C, systolic
blood pressure >90 mmHg, heart rate <100 beats per
minute, and normal white blood cell count or a decrease
of at least 2000 cells/μL over the last 24 hours. A transi-
tion to PO antibiotics was not expected when a patient’s
condition was unstable and in the case of erratic gastro-
intestinal absorption that can be due to either severe
acute diarrhea or vomiting.
Secondary outcomes were to evaluate the duration of
IV therapy and LOS, and to identify the type of conver-
sion used in relation to antibiotic classes when a switch
was done.
Statistical analysis
Statistical analysis was performed using the Statistical
Package for the Social Science software (SPSS version
20.0). Descriptive statistics were used to describe patient
characteristics (frequencies and percentages for categor-
ical variables), and mean (± standard deviation) for
continuous variables. The 2 groups of patients (i.e. con-
verted and not converted) were compared for statisti-
cally significant differences using chi-square or Fisher’s
exact tests for categorical variables, and student-t-test
for continuous variables (length of IV therapy and LOS),
as appropriate. All reported p-values were two-sided
with the alpha set at a significance of 0.05.
Results
Patient characteristics
The study was performed over a period of six months
from December 2013 to May 2014 in three Lebanese
university teaching hospitals. A total of 2073 patient ad-
missions were screened for inclusion, out of which 604
were excluded. The most common reasons for exclusion
were either the patients did not receive IV antibiotics or
received PO antibiotics. The remaining 1469 patients
taking IV antibiotics were further reviewed for inclusion
in the study out of whom 383 patients treated with 491
antibiotic courses met the inclusion criteria as shown in
Figure 1. Of these patients, 79 (20.6%) were on concurrentIV and PO antibiotics and 304 (79.4%) were on IV anti-
biotics only.
The characteristics of study sample are shown in
Table 1. Overall the mean age in years (± SD) of the pa-
tients was 59.68 (±18.99) years with 198 (51.7%) males.
From the enrolled patients, 261 (68.1%) had one or
more co-morbidities. The most frequent co-morbidities
encountered were hypertension (176, 46%) and diabetes
mellitus (144, 37.6%). All included patients were treated
on the ward to which they were initially admitted for at
least 3 days with IV antibiotics for at least 48 hours.
The most frequent site of infection was the respiratory
tract infections (188, 49.1%), followed by COPD exacer-
bation (99, 25.8%).
Prescribed antibiotic classes used for empirical therapy
were mostly β-lactams (335, 68.2%), followed by fluoroqui-
nolones (80, 16.3%). Patients received empirical treatment
either as monotherapy (281, 73.4%), or combination of
more than one IV antibiotic (102, 26.6%) with cephalospo-
rins (193, 39.3%) being the most commonly prescribed
antibiotics in the combination regimens. Microbiologically
documented infections accounted for 18% of the
prescriptions.
Modifications of antibiotic prescriptions
Switch from IV to PO therapy
Twenty-seven patients on thirty-nine (7.9%) antibiotic
courses did not meet the eligibility criteria for the switch
from IV to PO route and required to continue IV antibi-
otics. A total of 356 patients on 452 IV antibiotic courses
Table 1 Characteristics of study sample of switch eligible
patients
Characteristic Frequency (%)















Presumed or documented diagnosis
Respiratory tract infections 188 (49.1)
COPD exacerbation 99 (25.8)
Urinary tract infections 58 (15.1)
Skin & soft tissue infections 40 (10.4)
Gastrointestinal infections 24 (6.3)
Other infections 5 (1.3)
Abbreviations: CAD coronary artery diseases, COPD chronic obstructive































Figure 2 Frequency of IV to PO conversion among different
antibiotic classes in patients eligible for switch. The percentage
of IV to PO conversion was compared among different antibiotic
classes in patients eligible for switch in both the converted and
non-converted groups. P values were calculated by comparing
converted and non-converted antibiotics for each class; P-value
<0.05, statistically significant for the conversion of β-lactams
(p-value <0.001), macrolides & lincosamides (p-value = 0.009)
and fluoroquinolones (p-value <0.0001). Chi-square test used for
β-lactams, macrolides and fluoroquinolones, and metronidazole.
Fisher’s exact test used for glycopeptides and aminoglycosides.
Abbreviations: IV, intravenous; PO, oral.
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The IV antibiotic courses were divided into 300 (66.4%)
β-lactams, 33 (7.3%) macrolides, 78 (17.3%) fluoroquino-
lones, 25 (5.5%) metronidazole, and 16 (3.5%) aminogly-
cosides and glycopeptides. Out of the total 452 antibiotic
courses, 334 (73.9%) were not converted and IV anti-
biotics were administered beyond day 3, and 118 (26.1%)
of IV antibiotics were switched to PO route and there-
fore assumed eligible for conversion and met the criteria
for conversion with a p-value <0.0001. The percentage
of patients switched in a timely fashion was comparable
between the infection types with p-value >0.05 with the
lowest for skin and soft tissue infections (SSTI). The
majority of switch from IV to PO alternative (111, 94.1%)
was done early in therapy within 3 to 5 days of hospital
admission and 7 (5.9%) episodes were delayed in the
transition beyond day 5 of admission.
Correlation between antibiotic classes and switch from IV
to PO therapy
The associations between antibiotic classes and the fre-
quency of IV to PO switch eligible medication records
were studied as shown in Figure 2. Fluoroquinoloneswere the antibiotic class mostly converted although
other classes were eligible for switch. From the patients
who were converted to PO agent, conversion was dis-
tributed among classes as follows: 13.7% for β-lactams,
45.5% for macrolides, 60.3% for fluoroquinolones, 32%
for metronidazole, and 5.9% of aminoglycosides and
glycopeptides.
Correlation between pathogen-specific cultures and
switch from IV to PO therapy
During the evaluation period, 99 patients had positive
cultures. The correlation between the frequency of
switch and microbiologically documented infections was
statistically significant where switch over from IV to PO
therapy was done more in case of a confirmation of the
pathogen responsible for the infection with a p-value of
0.035 as shown in Table 2.
Type of IV to PO conversion
IV therapy was modified either by discontinuation or
switching to oral therapy – in the 118 episodes as shown
in Table 3. Out of the 118 episodes, antibiotic treatment
was discontinued in 36 antibiotics courses (30.5%) and a
switch to oral agents was done in 82 (69.5%) of anti-
biotic courses based on the predefined clinical criteria.
The mean time of switch was 3.81 days (± 1.15) at 95%
CI (3.60 – 4.02).
Table 2 Correlation between pathogen-specific cultures
and the frequency of switch from IV to PO antibiotics
Not switched Switched
N(%) N(%)
Negative culture 306 (82) 86 (72.9)
Positive culture* 67 (18) 32 (27.1)
*P-value = 0.035.
Chi-square test used for statistically significant differences.
Abbreviations: n frequency, % percentage, IV intravenous, PO oral.
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study was the sequential conversion therapy and the
most antibiotic drug classes involved were fluoroquino-
lones (87.5%), macrolides (80%) and metronidazole
(100%) with a p-value of <0.0001, for which both IV and
PO formulations are available for the same drug as
illustrated in Figure 3.
Duration of IV therapy and length of hospital stay
Overall, IV antibiotic therapy was continued for 5.39 ±
2.63 days and the LOS in days was 6.63 ± 2.74. Comparing
the 2 groups – converted versus not-converted medica-
tions records, the LOS was unchanged with no statistical
significance (p-value of 0.227); 6.61 days for the 118
patients treated with early switch versus 6.69 days for
those who remained on IV treatment. Nevertheless, there
was a trend towards a shorter overall duration of antibiotic
treatment as shown in Figure 4.
As expected, the duration of IV therapy of converted
medication records was shorter than those that were not
converted with p-value <0.0001 (95% CI, 2.73 – 3.74).
Combined use of IV antibiotics and PO medications
Because the ability to tolerate oral medications was used
as one of the criteria for switching patients, it was
worthwhile to record the number of PO antibiotic pre-
scriptions received by patients on IV therapy and was 79
(20.6%). Furthermore, the fact that patients received oralTable 3 Characteristics of IV to PO conversion therapy
types in patients that were switched to oral agent and its
effect on the length of IV therapy and length of stay






Days of IV therapy (mean ± SD) 2.86 ± 1.16
Length of hospital stay (mean ± SD) 6.56 ± 0.24
Chi-square and Fisher’s exact tests used for statistically significant differences.
Student t- test was used to analyze the length of hospital stay and duration of IV.
*P-value <0.0001.
Abbreviations: IV intravenous, PO oral, SD standard deviation, % percentage.drugs while on IV antibiotic therapy indicated that these
patients had no gastrointestinal absorption problems,
however only 12 (10.2%) of those patients were switched
with no statistical significance with a p-value >0.05.
Discussion
This study was done on the Lebanese population where
there is a need for unified local guidelines to the physi-
cians and clinical pharmacists to aid in the conversion
from IV to PO route when the condition of the patient
has improved after few days of hospital admission.
Various studies covered IV to PO conversion and their
implications in clinical practice as the reduction of the
prolonged use of IV antimicrobials and shortening of the
LOS. The present study was not designed to prove that
an early switch to PO therapy has the same efficacy as a
full IV course.
Most of the admitted patients, who are initially pre-
scribed IV antibiotics, can be switched to an appropriate
PO formulation once the clinical stability markers are
met, provided that the total course of therapy duration
is completed. Using the defined criteria for IV to PO
switch, two-third of the included patients in the study
were not switched to PO therapy, despite improvements
in clinical signs of infection. The number of patients that
were switched to PO therapy could have been underesti-
mated since the study design did not follow up dis-
charged patients. In the Lebanese practice, patients are
converted to PO antibiotic therapy once discharged
home, although a 24 hour-period after switch is required
for patient’s monitoring before discharge. Other possible
barriers to a timely switch strategy perceived by the
study results include unfamiliarity with guideline recom-
mendations, misconceptions or lack of outcome expect-
ancy. These barriers were also reflected by the study
results of Schouten et al. (Schouten et al. 2007) and
Halm et al. (Halm et al. 2001). Physicians were not
aware of the existence of clear guidelines on the ad-
equate timing of the switch. Indeed, participating hospi-
tals did not provide these guidelines through booklets or
educational sessions and did not adopt ASPs that may
be applied in few centers in Lebanon.
Modifications in IV antibiotics were done in one-third
of the antibiotic courses; interventions for switch were
either through discontinuation of therapy or conversion
to the alternative oral drug depending on the antibiotic
class that was prescribed. Administered antibiotic courses
of therapy that were switched to a suitable PO formulation
were few and involved mostly fluoroquinolnes, macrolides
and metronidazole classes probably because these an-
tibiotics are available in both PO and IV formulations
where sequential conversion type is used. Whereas the
number of antibiotic courses on β-lactams (specifically




























Figure 3 Percentage of conversion based on the different types of conversion therapy from IV to PO among the antibiotics classes
studied. The percentage of conversion was done based on the different types of conversion therapy from IV to PO (sequential, switch, and
step-down) among the different antibiotics classes studied. Statistical significance was observed with β-lactams and fluoroquinolones (p <0.0001),
and macrolides (p = 0.002) while no statistical significance (p > 0.05) obtained for the other classes. Fisher’s exact test was used for analysis.
Abbreviations: IV, intravenous; PO, oral.
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discontinuation of the drug on the day of clinical stability
rather than switching to PO therapy, similarly to the
observation done by Hunter and Dormaier (Hunter and
Dormaier 1995). As a further illustration about the
switch, drugs as ceftriaxone with no definitive oral
















Duration of IV antibiotics
Figure 4 Duration of IV therapy & length of hospital stay for
converted and not converted medication records. Comparison
between the duration of IV therapy and length of hospital stay for
converted and not converted medication records. Statistical
significance was observed with a P < 0.0001 for the duration of IV
therapy and no statistical significance with a p-value = 0.227 for the
length of hospital stay. Student t- test was used to analyze the
length of hospital stay and duration of IV antibiotics. Abbreviations:
IV, intravenous.step-down conversion therapy, which was minimally done
in this study.
The mean number of days to clinical stability and
therefore the time for switch in this study was 3.81 days,
correlated with the results of previous studies (Mertz
et al. 2009; Senn et al. 2004; Athanassa et al. 2008) that
also reported the appropriate time for IV therapy to be
reassessed between 2.0 - 4.0 days. In this study, the
mean length of IV therapy was around 7 days for non-
converted patients compared to around 4 days for the
converted ones. However, a reduction in the LOS was
not observed, similarly to Laing et al. (Laing et al. 1998)
even though the duration of IV therapy shortened in
patients who were converted which correlates with the
results of previous studies (Mertz et al. 2009; Laing
et al. 1998).
Antibiotic resistance is directly related to the excessive
use of antibiotics. Previous studies evaluating antibiotic
use in hospitals have shown that up to 50% of prescrip-
tions can be inappropriate (Goldmann et al. 1996;
McGowan 1994; Kollef et al. 1997; Thuong et al. 2000).
Hence limiting the misuse of antibiotics may be an im-
portant intervention for reducing levels of resistance.
Results of the study confirm the tendency of physicians
to prescribe broad-spectrum antibiotic therapy empiric-
ally with β-lactams mainly third-generation cephalospo-
rins followed by fluoroquinolones the most widely used
antibiotic classes among assessed patients. Therefore,
improving appropriateness of therapy at the time of
initial empirical prescribing is a difficult challenge as-
sociated with many organizational requirements and
governed by the hospital policy.
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The strengths of the study were that it was a multicenter
study where a large number of patients were screened.
The principle investigator recorded data without any
interference or bias. The study also assessed all classes
of antibiotics and different types of infections and
highlighted the vital role of clinical pharmacist to
hospital practice. Clinical pharmacists can follow a
defined protocol to daily assess patient eligibility for
an IV to PO switch, be in charge of the appropriate
route of the medication, and monitor the patient’s
progress and tolerability.
This study has several limitations. First, the study was
observational while an interventional study could have a
greater impact on the results. Second, lack of unified
documentation of patients’ information among the three
medical sites (paper based or computerized databases),
as well as difference in the physicians’ educational back-
ground. However the lack of uniformity between the
sites and the teams demonstrated that the evaluation
tool could be effectively used in a variety of clinical set-
tings. Third, although criteria for clinical stability were
defined and previously set to assist in the evaluation of
appropriate IV to PO conversion, the impact of other
factors that influenced clinical decisions (e.g. lack or
missing data for daily eligibility criteria, reasons for non-
conversion, complications due to co-morbidities) were
not assessed.
Conclusion
The results of this evaluation highlighted the need of a
structured approach and clear guidelines to appropri-
ately prescribe antibiotics and review the therapeutic
decisions including assessment for improvement in
patient’s clinical status for antibiotic conversion from
IV to PO therapy in daily practice. Further studies are
needed to assess physician’s knowledge, beliefs, and
acceptance of the switch over from IV to PO therapy
in order to establish an effective and unified guideline
for IV to PO conversion and consequently its implementa-
tion through team approach. This study did not measure
the reduction in complications from the IV to PO switch
since it was a retrospective observational study. Hence,
this raises the need for a future prospective research with
a pharmacist-involved intervention.
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